EXOZ 最新10-Q变化
将 EXOZ 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-13 与上一份 10-Q · 2026-05-14
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +39 | −14 | ~48 | 55 |
| 市场风险(第3项) | 文字有新增/删除 | +39 | −14 | ~47 | 55 |
| 控制与程序 | 文字有新增/删除 | +39 | −14 | ~47 | 55 |
| 法律诉讼 | 文字有新增/删除 | +39 | −14 | ~47 | 55 |
| 风险因素 | 文字有新增/删除 | +39 | −14 | ~47 | 55 |
| 其他信息 | 文字有新增/删除 | +39 | −14 | ~46 | 55 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-13
Change in fair value of derivative instruments 172,859 - 172,859 -
Issuance of common stock for exercise of options 291 - - - -
Issuance of common stock due to vesting of RSU 39,259 - - - -
Net cash provided by (used in) investing activities $(57,603) (61,920)
Net proceeds from issuance of common stock and warrants 5,861,147 -
相对上期删除的文字 · 来源:10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
The Company periodically reviews the financial condition of the financial institutions and assesses the credit risk of such investments. The Company may periodically have cash balances in financial institutions more than the FDIC insurance limits of $250,000. On March 31, 2026, the Company had appro…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
The warrants outstanding, issued, exercised, and expired, along with their respective exercise prices and expiration dates, as of December 31, 2025, and for the three months ended March 31, 2026, are presented below:
Grant Date Shares Granted Exercise Price ($) Vesting Term Expected Life (Years) Risk-Free Rate Expected Volatility
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-08-13
Change in fair value of derivative instruments 172,859 - 172,859 -
Issuance of common stock for exercise of options 291 - - - -
Issuance of common stock due to vesting of RSU 39,259 - - - -
Net cash provided by (used in) investing activities $(57,603) (61,920)
Net proceeds from issuance of common stock and warrants 5,861,147 -
相对上期删除的文字 · 来源:10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
The Company periodically reviews the financial condition of the financial institutions and assesses the credit risk of such investments. The Company may periodically have cash balances in financial institutions more than the FDIC insurance limits of $250,000. On March 31, 2026, the Company had appro…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
The warrants outstanding, issued, exercised, and expired, along with their respective exercise prices and expiration dates, as of December 31, 2025, and for the three months ended March 31, 2026, are presented below:
Grant Date Shares Granted Exercise Price ($) Vesting Term Expected Life (Years) Risk-Free Rate Expected Volatility
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-08-13
Change in fair value of derivative instruments 172,859 - 172,859 -
Issuance of common stock for exercise of options 291 - - - -
Issuance of common stock due to vesting of RSU 39,259 - - - -
Net cash provided by (used in) investing activities $(57,603) (61,920)
Net proceeds from issuance of common stock and warrants 5,861,147 -
相对上期删除的文字 · 来源:10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
The Company periodically reviews the financial condition of the financial institutions and assesses the credit risk of such investments. The Company may periodically have cash balances in financial institutions more than the FDIC insurance limits of $250,000. On March 31, 2026, the Company had appro…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
The warrants outstanding, issued, exercised, and expired, along with their respective exercise prices and expiration dates, as of December 31, 2025, and for the three months ended March 31, 2026, are presented below:
Grant Date Shares Granted Exercise Price ($) Vesting Term Expected Life (Years) Risk-Free Rate Expected Volatility
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-08-13
Change in fair value of derivative instruments 172,859 - 172,859 -
Issuance of common stock for exercise of options 291 - - - -
Issuance of common stock due to vesting of RSU 39,259 - - - -
Net cash provided by (used in) investing activities $(57,603) (61,920)
Net proceeds from issuance of common stock and warrants 5,861,147 -
相对上期删除的文字 · 来源:10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
The Company periodically reviews the financial condition of the financial institutions and assesses the credit risk of such investments. The Company may periodically have cash balances in financial institutions more than the FDIC insurance limits of $250,000. On March 31, 2026, the Company had appro…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
The warrants outstanding, issued, exercised, and expired, along with their respective exercise prices and expiration dates, as of December 31, 2025, and for the three months ended March 31, 2026, are presented below:
Grant Date Shares Granted Exercise Price ($) Vesting Term Expected Life (Years) Risk-Free Rate Expected Volatility
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-08-13
Change in fair value of derivative instruments 172,859 - 172,859 -
Issuance of common stock for exercise of options 291 - - - -
Issuance of common stock due to vesting of RSU 39,259 - - - -
Net cash provided by (used in) investing activities $(57,603) (61,920)
Net proceeds from issuance of common stock and warrants 5,861,147 -
相对上期删除的文字 · 来源:10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
The Company periodically reviews the financial condition of the financial institutions and assesses the credit risk of such investments. The Company may periodically have cash balances in financial institutions more than the FDIC insurance limits of $250,000. On March 31, 2026, the Company had appro…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
The warrants outstanding, issued, exercised, and expired, along with their respective exercise prices and expiration dates, as of December 31, 2025, and for the three months ended March 31, 2026, are presented below:
Grant Date Shares Granted Exercise Price ($) Vesting Term Expected Life (Years) Risk-Free Rate Expected Volatility
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-08-13
Change in fair value of derivative instruments 172,859 - 172,859 -
Issuance of common stock for exercise of options 291 - - - -
Issuance of common stock due to vesting of RSU 39,259 - - - -
Net cash provided by (used in) investing activities $(57,603) (61,920)
Net proceeds from issuance of common stock and warrants 5,861,147 -
相对上期删除的文字 · 来源:10-Q · 2026-05-14
Weighted average of common shares outstanding – basic and diluted 8,458,847 8,367,810
The Company periodically reviews the financial condition of the financial institutions and assesses the credit risk of such investments. The Company may periodically have cash balances in financial institutions more than the FDIC insurance limits of $250,000. On March 31, 2026, the Company had appro…
Research and development costs are expensed as incurred. Research and development costs consist primarily of compensation costs, fees paid to consultants, and other expenses relating to the development of eXoZymes’s technology. For the three months ended March 31, 2026, and 2025, research and develo…
The warrants outstanding, issued, exercised, and expired, along with their respective exercise prices and expiration dates, as of December 31, 2025, and for the three months ended March 31, 2026, are presented below:
Grant Date Shares Granted Exercise Price ($) Vesting Term Expected Life (Years) Risk-Free Rate Expected Volatility
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议